In a search for molecular markers of progression in prostate cancer by means of dierential display, we have identi®ed a new gene, which we have designated PTOV1. Semiquantitative RT ± PCR has established that nine out of 11 tumors overexpress PTOV1 at levels signi®cantly higher than benign prostatic hyperplasia or normal prostate tissue. The human PTOV1 protein consists almost entirely of two repeated blocks of homology of 151 and 147 amino acids, joined by a short linker peptide, and is encoded by a 12-exon gene localized in chromosome 19q13.3. A Drosophila melanogaster PTOV1 homolog also contains two tandemly arranged PTOV blocks. A second gene, PTOV2, was identi®ed in humans and Drosophila, coding for proteins with a single PTOV homology block and unrelated amino-and carboxyl-terminal extensions. A 1.8-Kb PTOV1 transcript was detected abundantly in normal human brain, heart, skeletal muscle, kidney and liver, and at low levels in normal prostate. Immunocytochemical analysis and expression of chimeric GFP-PTOV1 proteins in cultured cells showed a predominantly perinuclear localization of PTOV1. In normal prostate tissue and in prostate adenomas, PTOV1 was undetectable or expressed at low levels, whereas nine out of 11 prostate adenocarcinomas showed a strong immunoreactivity, with a focal distribution in areas of carcinoma and prostatic intraepithelial neoplasia. Therefore, PTOV1 is a previously unknown gene, overexpressed in early and late stages of prostate cancer. The PTOV homology block represents a new class of conserved sequence blocks present in human, rodent and¯y proteins. Oncogene (2001) 20, 1455 ± 1464.
Introduction
The prostate in aging males is highly susceptible to benign and malignant proliferative changes. Several genetic and molecular alterations are candidates for being responsible for the phenotypic conversion of normal or hyperplastic prostate cells into malignant, invasive cells (reviewed in LoÂ pez and Diamandis, 1998; Gottlieb et al., 1999; Jenster, 1999) . Structural and functional alterations aecting the androgen receptor or its signaling pathways are probably responsible for many of the biological and biochemical changes associated with the neoplastic transformation of prostate epithelial cells (Gottlieb et al., 1999; Jenster, 1999) . Other genetic changes, such as mutations in oncogenes (Shen et al., 1995; Sun et al., 1997) and tumor suppressor genes (Brooks et al., 1996; Meyers et al., 1998; Whang et al., 1998) have been implicated in the multistep sequence of prostate carcinogenesis (Whang et al., 1998) , and alterations in genes such as HPC1 (Smith et al., 1996) and BRCA1 (Fan et al., 1998) have been evaluated for their implication in familial forms of prostate cancer.
In the most common form of prostate cancer, carcinomatous cells arise as multifocal lesions against a background of hyperplastic tissue, called the zone of benign peripheral hyperplasia. These multiple carcinomatous lesions could represent either independent, genetically unrelated events or a ®eld eect whereby a carcinogenic insult results in the independent transformation of a ®eld of adjacent epithelial cells (Kallionemi and Visakorpi, 1996; Bostwick et al., 1997 Bostwick et al., , 1998 . Also, one malignant transforming event may have occurred and the progeny of a single cancer cell spread through the prostate, giving rise to topographically distinct but genetically related tumors. Alternatively, a germline genetic alteration could predispose to the evolution of multiple cancer lesions in the same prostate. The earliest recognizable lesion containing cells with malignant features in prostate cancer is prostate intraepithelial neoplasia (PIN), which is therefore considered the initial morphological manifestation of molecular events leading to a fully transformed phenotype (Bostwick, 1996) . Molecular markers of early events in the progression of prostate cancer are expected to be altered in PIN. Examples of such early markers are the loss of expression of the cyclindependent kinase inhibitor p27 (FernaÂ ndez et al., 1999) , or the overexpression of the EGF receptor (Harper et al., 1998) in PIN.
Both genetic and epigenetic approaches have been used to identify molecular determinants of neoplastic progression in prostate tumors. A widely used approach has been the analysis of expression patterns by dierential display (Liang and Pardee, 1992) , which has allowed the identi®cation of genes and proteins that could be relevant for these processes, such as PTI-1 (Shen et al., 1995) , tropomyosin, a subunit of cytochrome c (Wang et al., 1996) , ®bronectin, UEV-1 (Stubbs et al., 1999) , or previously unknown genes (Blok et al., 1995; Chang et al., 1997; Lucas et al., 1998; Ronidelli and Tricoll, 1999) . More recently, dierential hybridization on cDNA microarrays has been used for similar purposes (Lin et al., 1999) . Here, with the use of dierential display, we have identi®ed a new gene, overexpressed in prostate tumors, which we have named PTOV1. This gene codes for a protein that consists almost entirely of two strongly related sequence blocks arranged in tandem. These blocks are present and conserved in at least two distinct proteins, PTOV1 and PTOV2, in humans, rodents and ies. Immunohistochemical analysis with speci®c antibodies to PTOV1 indicates that this protein is expressed at high levels in early and late stages of prostate adenocarcinomas.
Results

PTOV1, a transcript overexpressed in prostate tumors
Microdissected prostate tumor samples were used as a source of RNA in dierential display experiments. From the patterns yielding signi®cantly stronger signals in lanes corresponding to areas of carcinoma, as compared to lanes from non-carcinomatous areas (benign peripheral zone) from the same tumor sample, one band, designated PTOV1 (prostate tumor overexpressed), was selected. The sequence of this band ( Figure 1a ) did not show signi®cant homologies to any known genes, although identities were found with numerous ESTs. Primers were designed for semiquantitative RT ± PCR analysis of the expression levels of PTOV1 transcripts in microdissected prostate tumor samples, prostate adenomas, and normal prostate tissue (Figure 1b,c) . Levels of PTOV1 transcripts were signi®cantly higher both in carcinomatous areas and in benign peripheral zones of prostate tumors, when compared to levels in adenomas (benign prostatic hyperplasias) (P50.0005 and P50.005, respectively), or normal prostate tissue (P50.01 and P50.04, respectively).
A search for sequences related to PTOV1 revealed numerous ESTs in human, mouse and rat databases, which contained sequences identical, or strongly related, to PTOV1. Primers were designed to encompass the longest possible cDNA from sequences assembled from the aligned ESTs, and used for reverse transcription, ampli®cation and cloning. Conceptual translation of the resulting cDNA predicts an open reading frame for a protein of 416 amino acids ( Figure  1a) , highly conserved between humans and rodents ( Figure 2a ). Further searches of publicly available genomic databases yielded a sequence from Drosophila melanogaster (acc. AC013074), predicted to encode a protein with signi®cant homology to the deduced human PTOV1 protein (Figure 2a) .
A new family of proteins with PTOV homology blocks
The deduced human PTOV1 protein consists almost entirely of two tandemly arranged blocks of sequence of 151 and 147 amino acids, strongly related to each other (66% identity; 79% similarity, allowing for conserved substitutions), joined by a short linker sequence (Figures 1a and 2a, b) . Secondary structure analysis predicts alternating stretches of alpha helices and beta sheets (Figure 2a) . Neither of these modules show signi®cant similarities to any known protein domain or motif. The same duplicated modular arrangement and similar secondary structure are predicted for the D. melanogaster PTOV1 homolog deduced for AC013074, although the degree of similarity between the two blocks of homology in thē y protein is lower (33% identity; 57% conserved) than that for the human protein (Figure 2b ).
The human PTOV1 gene was isolated, sequenced in its entirety and analysed for its architecture. The PTOV1 gene consists of 12 exons, of which exons 3 ± 6 code for the ®rst of the two repeated PTOV homology blocks, and exons 7 ± 11 for the second of the repeated blocks (Figure 3a) . The PTOV1 gene was assigned to 19q13.3 ± 13.4 by FISH analysis on human metaphase chromosomes (Figure 3b ). With posteriority to our analysis, un®nished and unordered genomic sequences for this entire region were released (acc. AC018766). The results of analysing these sequences (not shown) are largely in agreement with our experimentally deduced gene architecture, and further con®rm the chromosomal assignment for PTOV1.
A second PTOV1-related sequence was identi®ed on chromosome 19q13.3. Our analysis indicates that the H. sapiens genomic clones AC006942 and AC018766 (released as un®nished and unordered fragments) are contiguous (not shown), and the combined sequence is predicted to contain a 16-exon gene, 14 Kb upstream from the putative ®rst exon of PTOV1, and encoding a protein with one PTOV-like homology block. The rest of this predicted protein is unrelated to PTOV1, extending 308 residues towards the amino end and 184 residues towards the carboxyl end of the PTOV block. We have designated this gene PTOV2 ( Figure  4a Extensive database searches, including PSI-BLAST searches with each of the PTOV homology blocks (three iterations), and PHI-BLAST searches with sequence patterns generated from consensus sequences for all, or combinations, of the PTOV blocks, did not yield any signi®cant similarities to known genes or structures, with the exception of a distant but signi®cant similarity of the ®rst PTOV module of Drosophila PTOV1 to b-tubulin and the procaryotic tubulin-related protein FtsZ (not shown). Therefore, the PTOV repeat represents a previously unidenti®ed class of conserved protein blocks. Human, mouse and y PTOV1 consist almost entirely of two PTOV blocks arranged in tandem, whereas human and¯y PTOV2 consist of a single PTOV block placed between unrelated polypeptide segments.
Tissue range of PTOV1 expression
Northern blotting for PTOV1 on mRNAs from normal human tissues revealed a single transcript species of 1.8 kb, most abundant in brain, heart, skeletal muscle, kidney and liver ( Figure 5a ). Normal prostate expressed low levels of PTOV1 (Figure 5a ). Frequently, genes that are overexpressed in prostate cancer are subject to regulation by androgens. We thus tested whether the expression of PTOV1 could be modulated by exposure to 5-a-dihydroxytestosterone (DHT) of the androgen-dependent prostate tumor cell line LNCaP. Cells grown in steroid-depleted medium expressed low levels of PTOV1 (Figure 5b ). Exposure of LNCaP cells to 50 nM DHT induced a 1.5-fold increase in PTOV1 mRNA levels after 48 h, suggesting that expression of PTOV1 can be regulated by androgens.
Subcellular localization of PTOV1
Antibodies speci®c for the ®rst repeated PTOV1 block ( Figure 1a ) detected a 58 Kd protein in prostate tumor (Figure 5c ). Higher resolution electrophoresis identi®ed at least three closely migrating forms of PTOV1 (Figure 5d ). Protein levels in the tumor samples examined were 3 ± 10-fold higher than those in normal prostate samples (Figure 5d ). Immunocytochemical analysis of PC-3 prostate tumor cells revealed that endogenous PTOV1 is located mainly in the cytoplasm, mostly concentrated around the nucleus (Figure 5e ). Expression of exogenous PTOV1 in PC-3 cells from constructs bearing green¯uorescent protein in phase with PTOV1 (Figure 5c ), either at the amino or the carboxyl end of the protein, yielded subcellular localizations largely consistent with those observed with anti-PTOV1 antibody (Figure 5f ± h). In addition to its predominant perinuclear localization, some of the chimeric GFP-PTOV1 protein showed a intranuclear localization ( Figure 5 ).
Expression of PTOV1 protein in prostate tumors
Normal prostate tissues expressed PTOV1 at very low levels, as shown by Western blotting (Figure 5d ) and RT ± PCR (Figure 1b) , and was not detectable by immunohistochemical assays (Figure 6a ). Two samples of benign hyperplasia showed a weak staining at the apical border of glandular epithelial cells. In contrast, staining for PTOV1 was strong in nine out of 11 tumor samples, with a focal distribution in areas of carcinoma (Figure 6c ) or prostatic intraepithelial neoplasia ( Figure  6f ). In three samples, tumor cells reactive for PTOV1 presented a strong cytoplasmic and juxtanuclear staining, with a pattern consistent with that observed in cultured cells (Figure 6c , inlet). In two other cases, PTOV1 was present throughout the cytoplasm of positive cells. Areas of benign hyperplasia within the adenocarcinoma samples had consistently weaker and more homogeneous reactivities (Figure 6c,f) . PTOV1 was undetectable in transitional prostate tissue from the (Figure 6e ). Therefore, PTOV1 is markedly overexpressed in foci of prostate tumors with malignant morphological features, including PIN. It is also expressed at modestly elevated or at low levels, but with a homogeneous distribution, in morphologically normal cells located in benign peripheral zones of the same tumors (Table 1a) . Two out of nine samples of benign prostatic hyperplasia, for which no evidence was found for the presence of malignant cells, showed moderate levels of immunoreactivity for PTOV1 (Table 1b) . These results correlate well with the semiquantitative RT ± PCR determinations of PTOV1 RNA levels ( Figure 1 and Table 1 ). In the samples studied here, no correlation was observed between PTOV1 levels and other relevant parameters, such as histological grade, clinical stage or PSA levels (Table 1a) .
Discussion
We report here the identi®cation of PTOV1, a new gene and protein that is overexpressed in prostate tumors, including morphologically malignant cells and cells from prostate intraepithelial neoplasia lesions. Many genes and proteins have been reported that show increased levels of expression as a result of neoplastic transformation of prostate cells. Most of these molecules are expressed also in basal epithelial cells in normal prostate (Blok et al., 1995; Reiter et al., 1998; He et al., 1997; Troyer et al., 1995; Montironi et al., 1999; Guate et al., 1997) , and thus their expression in tumor cells can be considered a re¯ection either of the expansion of a population of proliferating cells, or the activation in tumor cells of pathways that are operative in normal proliferation. On the other hand, some genes and proteins overexpressed in prostate cancer cells are not expressed, or are not detectable, in normal prostate (Magi Galluzzi et al., 1997; Zhau et al., 1992) . PTOV1 is expressed at very low levels in normal prostate, detectable by Western blotting, although immunohistochemical analysis has not allowed us to determine the source cell type in which PTOV1 is expressed. The fact that PTOV1 is overexpressed in prostatic intraepithelial neoplasia, as well as in advanced-stage tumor cells, suggests that it is part of the abnormal transcriptional repertoire in the early stages of the development of prostate cancer.
The focal pattern of expression of PTOV1 in prostate cancer cells and in PIN would support the multifocal origin of this neoplasia (Bostwick et al., 1998; FernaÂ ndez et al., 1999) . Nonetheless, in all tumors, cells positive for PTOV1 included not only those with carcinomatous phenotypes, but also some areas of morphologically normal cells within the benign peripheral zone. This would suggest that a common factor triggers the expression of PTOV1 in all peripheral epithelial cells in prostate tumors. Such a factor may or may not be causally related to the oncogenic events responsible for the malignant transformation of these cells. From a clinical and pathological standpoint, detection of PTOV1 could be of diagnostic aid in prostate cancer, since it is found overexpressed in premalignant cells from prostate tumor samples, such as those in prostate intraepithelial neoplasia. Furthermore, since PTOV1 can be overexpressed at detectable The chromosomal region where PTOV1 is located, 19q13.3 ± 13.4, harbors a large number of genes whose expression can be modulated by androgens. The expression of PTOV1 itself appears to be regulated by androgens. Many of these genes and their encoded proteins have been implicated in prostate cancer and other hormone-dependent tumors, and they include the apoptosis regulator bax-d (Johnson et al., 1998) , or for the proteases prostate speci®c antigen, kallikrein 1, prostatic kallikrein 2 , TLSP , nes1 (Goyal et al., 1998) , or zyme/neurosin (Yousef et al., 1999) . It is possible that overexpression of PTOV1 in prostate cancer forms part of a coordinated response to abnormal androgenic stimuli in tumor cells, aecting their proliferative behavior and invasive capabilities.
Human PTOV1 consists almost entirely of a tandem duplication of a new class of sequence homology blocks conserved across distant organisms. Drosophila PTOV1 also consists of a duplicated PTOV block. The sequence and structure of the PTOV1 protein provides few clues as to its function, or the biochemical pathways in which it could be involved. The only clue ± 4) , and normal prostates (lane 5). All bands visible in the 55 ± 60 Kd range were absent when samples were probed with pre-immune serum. (e) Combined confocal immuno¯uorescent and transmission images of untransfected PC-3 cells stained with anti-PTOV1. (f,g) PC-3 cells transfected with GFP-PTOV1, visualized in the green channel for GFP-PTOV1 (f) or the red channel for PTOV1 detected with anti-PTOV1 antibody (g). Both channels were merged in (h). Control transfections with pEGFP alone yielded diuse homogeneous patterns of¯uorescence without a speci®c subcellular localization (not shown). Scale bar, 10 mM is a distant homology of the ®rst PTOV block of Drosophila PTOV1 to b-tubulin, re¯ected solely as a predicted secondary structure reminiscent of the folding of b-tubulin (Nogales et al., 1998) . However, PTOV1 and its homologs lack all of the sequence features essential for the function of tubulins. The modular nature of the PTOV1 motif is inferred from: (i) its presence as a tandemly arranged duplicated repeat block in human, mouse and¯y PTOV1; and (ii) the presence of a single PTOV block as part of two other predicted proteins, human and Drosophila PTOV2. Therefore, despite the lack of structural and functional information on the PTOV sequence block, its presence as a modular element in dierent proteins suggests its involvement in novel forms of protein ± protein interactions. Experiments are presently underway to examine the nature of such interactions.
Materials and methods
Tissue specimens
Tissue specimens were obtained from patients with clinically localized disease undergoing radical or open prostatectomy.
Normal prostates were from organ donors. None of the patients included in the study received chemotherapy, radiotherapy or hormonal therapy prior to surgery. Each tumor was characterized for pathological (Gleason) grade (Table 1) . Specimens (3 mm side cubes) were snap-frozen in liquid nitrogen immediately after surgery, and stored at 7808C thereafter. The ®rst and last of 10 serial 5 mM cryostat sections were H-E stained and evaluated for tumor cell content and location. The rest of the serial sections were labeled at the selected sites, microdissected at 7208C, and processed for RNA extraction.
Differential display
Carcinomatous and non-carcinomatous areas from cryostat sections were separately microdissected with the guidance of morphological analysis of serial sections stained by hematoxylin-eosine, and mRNAs isolated with the QuickPrep kit from Pharmacia (Uppsala, Sweden). Dierential display was performed essentially as described (Liang and Pardee, 1992) . Pattern comparisons were performed between carcinomatous vs non-carcinomatous input mRNAs from the same patient. Bands selected from dierential display gels were excised, eluted and a fraction reampli®ed. PCR products were cloned into pCRII (Invitrogen, San Diego, CA, USA) and sequenced from both strands. 
Semiquantitative RT ± PCR
Aliquots of oligo-dT primed RT reactions were ampli®ed in reactions containing 1 mM speci®c primers (PTOV1FOR, 5'-CAC CAT CCT CCA TGT TGC TG-3'; PTOV1REV, 5'-TCT TCA TTG GCC TCA TCC CC-3'), 50 mM Tris HCl, pH 8.3, 1.5 mM Cl 2 Mg, 0.4 mM dNTPs, and 0.5 units of Taq polymerase in a ®nal volume of 25 ml. PCR products were separated on 2% agarose gels and visualized with ethidium bromide. The intensity of the bands was quantitated, and normalized in reference to the products of ampli®cation for transcripts for the ribosomal protein S14r or cyclophilin A. Saturation curves were established for all ampli®cation products at increasing concentrations of input cDNA and increasing number of cycles. Determinations were done in triplicate, in at least three separate experiments. Statistical analyses were performed by the Student's t-test on the values (mean+s.e.m.) obtained from normalized densitometric determinations for ethidium bromide-stained gels. Values of P50.05 were taken as signi®cant.
Sequence analysis
BLAST (Altschul et al., 1990) and PSI-BLAST (Altschul et al., 1997) were used for homology searches against protein and nucleic acid databases. Related protein sequences were aligned with ClustalW. Secondary structure predictions were performed with the PHD package. Gene predictions were performed with the algorithms Genscan (Burge and Karlin, 1997) and GeneID (GuigoÂ et al., 1992) , and supported by stringent (E4e
710
) tblastx and blastn alignments with ESTs in GenBank's dbest.
Northern blotting
Nylon membranes with mRNAs from normal human tissues (Clontech, Palo Alto, CA, USA) were used. For certain samples, mRNA was isolated and 2 mg electrophoresed on 1% denaturing agarose gels, blotted onto nylon and UV cross-linked. Probes were labeled with a-32 P-dCTP by random-prime labeling. Hybridization was done overnight at 658C in 0.5 M Na 2 HPO 4 , pH 7.2, 7% SDS. Membranes were washed at high stringency and exposed to ®lm at 7808C. Films from three separate experiments were used for densitometric determinations.
Gene isolation and chromosomal assignment
A human genomic BAC library was screened with a 32 Plabeled PTOV1 probe. Clones positive after two rounds of screening were analysed and sequenced following a PCRbased strategy. For¯uorescent in situ hybridization (FISH), cDNA probes were labeled with biotin 16-dUTP, hybridized overnight on human metaphase chromosomes at 378C, and visualized with avidin-¯uorescein isothiocyanate (Vector Laboratories, Burlingham, CA, USA).
Antibodies and immunoassays
Rabbit antisera were generated against the peptide KRRPYSDSTAKLKR, corresponding to residues 104 ± 117 of PTOV1 (Figure 1a) , conjugated to KLH. For Western blotting, 50 mg of tissue or cell lysates were electrophoresed and transferred to nitrocellulose. Membranes were blocked for 1 h with blocking buer (5% non fat dry milk (NFDM) Sections from paran-embedded tissues were treated with xylene and rehydrated by sequential equilibration with graded ethanol solutions (100% ± 90% ± 70%). Antigen was retrieved by treatment of citrate buer-covered samples in a pressure cooker for 2.5 min. Sections were sequentially incubated with blocking buer, 3% H 2 O 2 for 7 min, primary antibody (1 : 1000 in blocking buer) for 30 min, goat anti-rabbit lg conjugated to peroxidase labeleddextran, and DAB substrate-chromogen (DAKO). Preimmune serum was used as a negative control.
Expression constructs and transfection
Constructs for the expression of chimeric GFP-PTOV1 were generated in pEGFP (Clontech) by placing the full-length PTOV1 cDNA in frame with GFP, either at the amino or the carboxyl termini of PTOV1. Transient transfection was done with Lipofectamine (GIBCO ± BRL, Grand Island, NY, USA) on PC-3 cells cultured on coverslips. Forty-eight hours after transfection, cells were washed, ®xed in 4% paraformaldehyde, processed for immuno¯uorescence with anti-PTOV1, mounted and analysed by confocal microscopy. Control transfections were performed with the vector pEGFP alone, for the expression of non-chimeric GFP, which consistently yielded a diuse¯uorescence distributed throughout the cells, without any organ-or subcellular structure-speci®c localizations.
